MedTrace Logo

A Study to Learn About a Vaccine Against E Coli in Healthy Adults

NCT07122986 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2026-04-30

No results posted yet for this study

Summary

This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.

Conditions

  • Healthy Participants

Interventions

DRUG

E coli vaccine 1 Dose A

Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval

DRUG

E coli vaccine 1 Dose B

Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval

DRUG

E coli vaccine 2

Candidate E coli vaccine 2, administered according to a 0, 6-month interval

DRUG

E coli vaccine 3

Candidate E coli vaccine 3, administered according to a 0, 6-month interval

DRUG

E coli Vaccine 4 Dose A

Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval

DRUG

E coli Vaccine 4 Dose B

Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval

DRUG

E coli Vaccine 4 Dose C

Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval

DRUG

E coli Vaccine 5 Dose A

Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval

DRUG

E coli Vaccine 5 Dose B

Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval

DRUG

Placebo

Placebo administered according to a 0, 6-month interval

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-11
Primary Completion
2028-05-26
Completion
2028-05-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07122986 on ClinicalTrials.gov